...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Trial design Faulty

"he makes a good point what do you guys think?"

A oversimplification of cardiovascular outcomes trials that incorrectly assumes too much identity between two very different patient populations in REDUCE-IT vs. BETonMACE and also fails to acknowledge that different drugs/mechanisms of action can give rise to very different patterns of Kaplan-Meier curve separation. Not all successful CVOT Kaplan-Meier's look like REDUCE-IT.

BDAZ

Share
New Message
Please login to post a reply